Compare Home Depot Inc (HD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Summit Therapeutics Inc — how do they compare? Home Depot Inc trades at $332.79 (market cap $332.08B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Home Depot Inc is far larger — about 31.7× Summit Therapeutics Inc's market cap, and Home Depot Inc pays a 2.8% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HD | SMMT | |
|---|---|---|
Market Cap | $332.08B | $10.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $29.32 |
52-Week Low | $297.51 | $13.05 |
Enterprise Value | $393.64B | $9.90B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $330.95, down 2.34% on the day, approaching its 52-week low amid broader market weakness in home improvement stocks. The company reported mixed quarterly earnings with a Q3 2025 miss but subsequent beats, while maintaining solid profitability with 8.41% net margins and strong ROE of 128.38%. Technical indicators show a bearish trend with key support at $321, while analysts maintain a predominantly bullish outlook with a $370.59 consensus price target representing 12% upside potential.
The outlook balances near-term headwinds from weakening big-ticket demand and rising mortgage rates against long-term strengths in Pro segment growth and housing market tailwinds. Investment opportunities include the stock's discount to analyst targets and resilient business model, while risks include margin pressure from investments, competitive threats, and sensitivity to housing market cycles.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
